{
  "docId": "019de072-7781-7512-96cc-a2b05ce755c7",
  "docSlug": "b1746432eb5f270eac90273cddb862aa",
  "documentTitle": "Bionomics | Investor Presentation Deck | 38 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 38,
  "prevPage": 37,
  "nextPage": null,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide details a specific business development milestone involving a licensing deal and potential revenue streams.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-7781-7512-96cc-a2b05ce755c7/38",
  "deckHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7",
  "deckJsonHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7.json",
  "deckAnchorHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.05,
        "y": 0.0034500000000000004
      },
      "kind": "image",
      "text": "carina biotech",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5396ee78-3dfe-46ce-ac1e-c48321ce02da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.51,
        "x": 0.46,
        "y": 0.00135
      },
      "kind": "list",
      "text": "Exclusive Agreement to license Bionomics' BNC101 oncology drug candidate to Carina Biotech for the development of Chimeric Antigen Receptor T cell (CAR-T) therapy, which harnesses the body's immune system to fight cancer.\nBionomics is eligible to receive up to A$118 million in clinical & development milestones plus royalty payments if Carina fully develops and markets the new therapy. In the event that Carina sub-licenses the CAR-T treatment, Bionomics is eligible to share in the sub-licensing revenues in early clinical development and receive a substantial double-digit portion of the revenues in later stages of clinical development.\nIn September 2021, Carina announced that it plans to initiate a clinical trial of BNC101 CAR-T therapy for the treatment of advanced colorectal (bowel) cancer in late 2022\nBionomics retains BNC101 for other types of therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ade88f5-510c-4bfc-bde8-c938147aa754",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.39,
        "x": 0.03,
        "y": 0.00175
      },
      "kind": "title",
      "text": "Exclusive BNC101 Oncology License Agreement for the Development of CAR-T Therapeutics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f68418e-07b3-4c8d-8705-227bec2efa3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.62,
        "x": 0.09,
        "y": 0.03
      },
      "kind": "title",
      "text": "Legacy Oncology Asset Monetization to Drive Value: BNC101",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa772124-8bc7-460f-a771-c8038d7a0103",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "8a923516-f8ab-4e4f-9ab4-e73f2d61e488",
      "evidence": "The slide presents a clear 'before' state (legacy oncology assets) and an 'after' state (monetization of these assets through a licensing agreement), which aligns with the before-after-bridge tool.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}